Yoshihiro Arai
Chief Executive Officer chez SOLASIA PHARMA K.K.
Fortune : 251 737 $ au 31/03/2024
Profil
Yoshihiro Arai is currently the President, CEO & Representative Director at Solasia Pharma KK since 2013.
Previously, he worked as a Principal at Amgen KK and Searle Yakuhin KK.
He holds an MBA from the University of Wales (Bangor) and has undergraduate and graduate degrees from Tokyo University of Pharmacy & Life Science.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SOLASIA PHARMA KK
0,65% | 31/12/2023 | 1 154 545 ( 0,65% ) | 251 737 $ | 31/03/2024 |
Postes actifs de Yoshihiro Arai
| Sociétés | Poste | Début |
|---|---|---|
| SOLASIA PHARMA K.K. | Chief Executive Officer | 01/02/2013 |
Anciens postes connus de Yoshihiro Arai
| Sociétés | Poste | Fin |
|---|---|---|
| Searle Yakuhin KK | Corporate Officer/Principal | - |
Amgen KK
 Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The private company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million. | Corporate Officer/Principal | - |
Formation de Yoshihiro Arai
| University of Wales (Bangor) | Masters Business Admin |
| Tokyo University of Pharmacy & Life Science | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SOLASIA PHARMA K.K. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Amgen KK
Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The private company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million. | Health Technology |
| Searle Yakuhin KK |
